Filtered By:
Cancer: Non-Small Cell Lung Cancer

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 53 results found since Jan 2013.

Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis
AbstractBrain metastases are especially common in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with a cumulative incidence of over 50% and associated with a poor prognosis, high symptom burden, and decreased quality of life. Lorlatinib is a brain-penetrant, third-generation ALK tyrosine kinase inhibitor (TKI), which has a high potency against resistance mutations seen with earlier generation ALK TKIs. In 2018, lorlatinib was granted accelerated approval in second- and third-line treatment for use in patients withALK-positive metastatic NSCLC on the basis of phase  1/2 study results. This i...
Source: Advances in Therapy - August 12, 2023 Category: Drugs & Pharmacology Source Type: research

Controversies in NSCLC: Do We Have Consensus?
Dr. Mark Kris reports on the current status of such NSCLC controversies as maintenance therapy and mutation testing, as discussed at the 2013 meeting on Targeted Therapies in Lung Cancer.
Source: Medscape Pathology and Laboratory Medicine Podcast - April 17, 2013 Category: Laboratory Medicine Authors: Medscape Source Type: podcasts

Afatinib Approved! Good News in Lung Cancer
Dr. Mark Kris welcomes the news of the FDA’s approval of afatinib and discusses best practices in the use of this drug in patients with non-small cell lung cancer.
Source: Medscape Pulmonary Medicine Podcast - July 12, 2013 Category: Respiratory Medicine Authors: Medscape Source Type: podcasts

Howard (Jack) West, MD - Updates in NSCLC Management: What Does the Future Hold for First‐Line Therapy?
Source: PeerView CME/CE Audio Podcast - Oncology - July 11, 2013 Category: Cancer & Oncology Authors: Answers in CME Tags: Science, Medicine Source Type: podcasts

Jyoti D. Patel, MD - Novel Therapies for NSCLC: Management of Disease Beyond Progression
Source: PeerView CME/CE Audio Podcast - Oncology - August 13, 2013 Category: Cancer & Oncology Authors: Answers in CME Tags: Science, Medicine Source Type: podcasts

Howard (Jack) West, MD - Updates in NSCLC Management: What Does the Future Hold for First‐Line Therapy?
Source: PeerView CME/CE Audio Podcast - Oncology - July 11, 2013 Category: Cancer & Oncology Authors: Answers in CME Tags: Science, Medicine Source Type: podcasts

Squamous Cell NSCLC: Finally Targetable?
Dr. Maurie Markman reviews a recent study looking at genetic mutations and possible therapeutic targets in squamous cell carcinoma of the lung.
Source: Medscape Pathology and Laboratory Medicine Podcast - February 11, 2014 Category: Laboratory Medicine Authors: Medscape Source Type: podcasts

10 Years of TKI Therapy in Lung Cancer
Dr. Mark Kris looks back at a fateful discovery and underscores the importance of testing for genetic mutations in every patient with non-small cell lung cancer.
Source: Medscape Pulmonary Medicine Podcast - February 28, 2014 Category: Respiratory Medicine Authors: Medscape Source Type: podcasts

Afatinib Approved! Good News in Lung Cancer
Dr. Mark Kris welcomes the news of the FDA’s approval of afatinib and discusses best practices in the use of this drug in patients with non-small cell lung cancer.
Source: Medscape Pulmonary Medicine Podcast - July 12, 2013 Category: Respiratory Medicine Authors: Medscape Source Type: podcasts

Controversies in NSCLC: Do We Have Consensus?
Dr. Mark Kris reports on the current status of such NSCLC controversies as maintenance therapy and mutation testing, as discussed at the 2013 meeting on Targeted Therapies in Lung Cancer.
Source: Medscape Pathology and Laboratory Medicine Podcast - April 17, 2013 Category: Laboratory Medicine Authors: Medscape Source Type: podcasts

Small Pleural Effusions Big Deal in NSCLC
Dr. Mark Kris reports on a study that indicates that even minimal pleural effusions are important prognostic factors in patients with non-small cell lung cancer, especially in early-stage disease.
Source: Medscape Pulmonary Medicine Podcast - April 28, 2014 Category: Respiratory Medicine Authors: Medscape Source Type: podcasts

An Agent Not Well MET in Lung Cancer
Dr. Mark Kris reports on 2 studies on MET inhibition in NSCLC that underscore the importance of defining the patient population who would benefit from a targeted therapy.
Source: Medscape Pulmonary Medicine Podcast - July 14, 2014 Category: Respiratory Medicine Authors: Medscape Source Type: podcasts

David R. Spigel, MD - Surveying a Changing Landscape: Recent Advances and Emerging Paradigms in Targeted and Immune-Based Therapies for NSCLC
Surveying a Changing Landscape: Recent Advances and Emerging Paradigms in Targeted and Immune-Based Therapies for NSCLC
Source: PeerView CME/CE Audio Podcast - Oncology - March 24, 2015 Category: Cancer & Oncology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts